Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization

Contributed by: PR Newswire

Tags

Porton-Class-C

More Like This

China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy

Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance

Porton Advanced Stem Cell Exosomes Granted INCI Status, Advancing into Global Cosmetic Ingredient Market

PR Newswire associated0

Cambrex Advances US and European Expansions

Alcura Obtains Manufacturing and Importation Authorization License, Expanding its Capabilities to Support Cell & Gene Therapy Developers

PR Newswire associated0

Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform

PR Newswire associated0

Minaris Advanced Therapies launches as the leading global partner dedicated to cell therapy development, manufacturing, and testing

Ardena’s New State-of-the-Art Nanomedicine Facility Secures Full GMP Approval for Manufacturing